Lonza Group AG

Lonza Group is a Basel-based Swiss biopharmaceutical CDMO founded in 1897 and now the world's second-largest biologics manufacturing outsourcer, with 2025 revenue of CHF 6.53B split between Biologics (70%, mAb / ADC / CGT / mRNA manufacturing) and Capsules & Health Ingredients (30%). The core thesis is that its 2024 strategic reset, including the USD 1.2B acquisition of Roche's Vacaville site in California, the divestiture of Specialty Ingredients, and the arrival of CEO Wolfgang Wienand, positions Lonza as one of only two scaled mammalian biologics capacity leaders above 200,000L, alongside Samsung Biologics, with additional policy tailwinds from the BIOSECURE Act against WuXi Biologics. Rating Hold: a high-quality CDMO compounder with visible recovery and upside catalysts, but a thin margin of safety at the current price.